Identification of the drug-metabolizing enzymes under development is considered very important because inter-individual variation due to drug interaction or SNPs should be avoided. We conduct analysis of a variety of enzymes such as CYP, FMO, MAO, UGT and hydrolases. We can design suitable test systems in compliance with various guidelines by combining an expression system, specific inhibitors and antibody. Examinations by various measurement methods such as HPLC with radioactive detection and LC/MS/MS are possible.

We conduct CYP inhibition studies using human liver microsome to predict drug interaction. The inhibition activity of a test substance is examined using validated metabolic reactions. The IC₅₀ and Ki values are calculated, and the inhibition activity over time is evaluated.

For others, we evaluate the effects of inhibitors on metabolism of a commercially available drug through the establishment of a system for measuring its metabolites and calculating the kinetic parameters using human microsomes and human frozen hepatocytes, etc.